Sunday, November 29, 2015 12:21:33 PM
The fact that he suddenly has left the stage speeks for itself. China is his last hope!
Doing business with Chinese is much more riskyer then doing business in the Western Society.
With FDA approval and a Market who shows lot of interests in Lympro,
AMBS would have Body. That's a better moment to go in talks with your investors. In this stage an investor with the right amount of money makes the deal. AMBS plays the second violin.
This step is a step in the wrong direction
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM